ow-molecular-weight heparin in constituted vascular intrauterine growth restriction. Randomized multicenter trial - GROWTH

CHU Saint-Etienne0 个研究点目标入组 162 人开始时间: 2019年2月8日最近更新: 2020年6月8日

适应症

试验速览

暂无简介。

•Patient over 18 years at > 22 and 34 weeks of gestation (WG) with vascular IUGR defined by :
•- estimated fœtal weight below the 10th percentile
•- clinical and ultrasound findings suggesting pathologically impaired growth or diminished fœtal well-being
•- clinical and ultrasound findings suggesting placental insufficiency
•Precise dating of pregnancy by ultrasound between 11 WG and 13 WE +6days
•Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 162
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Multiple pregnancy or identified cause of IUGR other than vascular
•- Patient with an immediate indication for fœtal extraction
•- Women with a history of venous thromboembolism or already treated with an anticoagulant
•- Women with contraindication to enoxaparin treatment at prophylactic doses
•Patient refusing to participate or unable to consent
•Platelet count < 80,00 platelets/mm3 at the initial assessment
•Patient denying self injection

发起方

CHU Saint-Etienne